MA53162A - Sel de xinafoate d'un composé inhibiteur de jak - Google Patents

Sel de xinafoate d'un composé inhibiteur de jak

Info

Publication number
MA53162A
MA53162A MA053162A MA53162A MA53162A MA 53162 A MA53162 A MA 53162A MA 053162 A MA053162 A MA 053162A MA 53162 A MA53162 A MA 53162A MA 53162 A MA53162 A MA 53162A
Authority
MA
Morocco
Prior art keywords
inhibitor compound
jak inhibitor
xinafoate salt
xinafoate
salt
Prior art date
Application number
MA053162A
Other languages
English (en)
Inventor
Carl-Johan Aurell
James Mccabe
Anna Matilda Angelica Pettersen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA53162A publication Critical patent/MA53162A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
MA053162A 2018-07-18 2019-07-17 Sel de xinafoate d'un composé inhibiteur de jak MA53162A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862699955P 2018-07-18 2018-07-18
US201962866013P 2019-06-25 2019-06-25

Publications (1)

Publication Number Publication Date
MA53162A true MA53162A (fr) 2021-05-26

Family

ID=67396927

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053162A MA53162A (fr) 2018-07-18 2019-07-17 Sel de xinafoate d'un composé inhibiteur de jak

Country Status (13)

Country Link
US (1) US11149029B2 (fr)
EP (1) EP3823964A1 (fr)
JP (2) JP7422732B2 (fr)
KR (1) KR20210033474A (fr)
CN (1) CN112424187A (fr)
AU (1) AU2019304014B2 (fr)
BR (1) BR112021000467A2 (fr)
CA (1) CA3105585A1 (fr)
IL (1) IL280025A (fr)
MA (1) MA53162A (fr)
MX (1) MX2021000611A (fr)
SG (1) SG11202100240RA (fr)
WO (1) WO2020016302A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697495C (fr) 2007-09-05 2013-02-05 Pfizer Limited Xinafoate de n4-[(2,2-difluoro-4h-benzo[1,4 oxazin-3-one)6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]pyrimidine-2,4-diamine
BR112013006016A2 (pt) * 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
CN105658646B (zh) * 2013-11-01 2018-11-27 诺华股份有限公司 作为激酶抑制剂的氨基杂芳基苯甲酰胺
PT3189045T (pt) 2014-08-11 2022-03-17 Sun Pharmaceutical Ind Ltd Novos sais de nilotinib e polimorfos do mesmo
MX2018003590A (es) * 2015-09-25 2018-11-29 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos y metodos para la inhibicion de jak.
KR102585048B1 (ko) * 2017-01-17 2023-10-05 아스트라제네카 아베 Jak1 선택적 억제제
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法

Also Published As

Publication number Publication date
MX2021000611A (es) 2021-04-13
JP2024001109A (ja) 2024-01-09
US20200062737A1 (en) 2020-02-27
SG11202100240RA (en) 2021-02-25
KR20210033474A (ko) 2021-03-26
IL280025A (en) 2021-03-01
WO2020016302A8 (fr) 2020-11-12
WO2020016302A1 (fr) 2020-01-23
US11149029B2 (en) 2021-10-19
BR112021000467A2 (pt) 2021-04-06
AU2019304014B2 (en) 2022-08-18
CN112424187A (zh) 2021-02-26
JP7422732B2 (ja) 2024-01-26
CA3105585A1 (fr) 2020-01-23
JP2021530526A (ja) 2021-11-11
EP3823964A1 (fr) 2021-05-26
AU2019304014A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
DK3880670T3 (da) Forbedret syntese af nøglemellemprodukt af kras-g12c-hæmmerforbindelse
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
CY1120705T1 (el) Καινοφανεις αναστολεις αποακετυλασων ιστονων
MA52942A (fr) Composés inhibiteurs d'oga
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MA52939A (fr) Composés inhibiteurs d'oga
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
IL269410B2 (en) Synthesis of mcl-1 inhibitor
SG11202103042XA (en) 2-azabicyclo hexane compound as jak inhibitor
MA43318A (fr) Nouveau composé de biphényle ou un sel de celui-ci
MD3810602T2 (ro) Compuşi
ZA201906817B (en) Methods of treatment using a jak inhibitor compound
EA201791684A1 (ru) Селективные ингибиторы bace1
EP3619208C0 (fr) Formes cristallines d'un composé inhibiteur de jak
MA47420A (fr) Composés inhibiteurs d'oga
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
MA54702A (fr) Composé pyrimidine ou sel correspondant
MA56001A (fr) Formes de sel cristallin d'un inhibiteur de kinase
IL269695A (en) Compounds useful as ALCAT 1 inhibitors
MA47129A (fr) Sel de composé pipéridine substitué
PH12019501317A1 (en) Polymorphs of herbicidal sulfonamides
MA53162A (fr) Sel de xinafoate d'un composé inhibiteur de jak
MD3504208T2 (ro) Derivat de triazolopirazinonă util în calitate de inhibitor al PDE1 uman
MA52936A (fr) Composés inhibiteurs d'oga
MA52937A (fr) Composés inhibiteurs d'oga